Comparative Pharmacology
Head-to-head clinical analysis: AMNESTEEM versus SORIATANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMNESTEEM versus SORIATANE.
AMNESTEEM vs SORIATANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Retinoid that binds to and activates retinoic acid receptors (RARs), thereby normalizing keratinocyte differentiation and reducing sebum production.
Retinoid that binds to nuclear retinoic acid receptors (RARs), modulating gene expression involved in cell proliferation, differentiation, and apoptosis.
0.5-1.0 mg/kg/day orally in 2 divided doses
Initial: 25-50 mg orally once daily; maintenance: 25-50 mg orally once daily; not to exceed 75 mg/day.
None Documented
None Documented
Terminal elimination half-life: 10-20 hours (mean 17 hours) in patients with normal renal function; prolonged in severe renal impairment
Terminal elimination half-life of etretinate (active form) is ≈100–125 days due to storage in adipose tissue; clinically relevant for prolonged teratogenicity.
Renal (65-83% as unchanged drug and metabolites), fecal (15-35% as metabolites)
Primarily hepatic metabolism; eliminated via feces (≈60%) and urine (≈15%) as metabolites; parent drug not excreted unchanged.
Category C
Category C
Retinoid
Retinoid